Citations

Clear

941 citation(s) found for "Tefferi, A".

Going Beyond 7 + 3 Regimens in the Treatment of Adult Acute Myeloid Leukemia
Tefferi, Ayalew , Letendre, Louis

Mayo Clinic

Journal of Clinical Oncology | April 24, 2012 | Volume: 30 | Issue: 20 | Pages: 2425-2428

10.1200/jco.2011.38.9601 | PMID 22529263 Get It

Overcoming “aspirin resistance” in MPN
Tefferi, Ayalew

Mayo Clinic

Blood | April 12, 2012 | Volume: 119 | Issue: 15 | Pages: 3377-3378

10.1182/blood-2012-02-406645 | PMID 22500051 Get It

In this issue of Blood, Pascale and colleagues show that biochemical resistance to aspirin in patients with essential thrombocythemia (ET) can be reversed by twice-daily dosing.1
Polyclonal Immunoglobulin Free Light Chain Levels Predict Survival in Myeloid Neoplasms
Pardanani, Animesh , Finke, Christy M. , Rajkumar, S. Vincent , Ketterling, Rhett P. , Hanson, Curtis A. , Katzmann, Jerry A., Tefferi, Ayalew , Lasho, Terra L. , Singh, Preet Paul , Rajkumar, S Vincent , Ketterling, Rhett P

Mayo Clinic

Journal of Clinical Oncology | February 14, 2012 | Volume: 30 | Issue: 10 | Pages: 1087-1094

10.1200/jco.2011.39.0310 | PMID 22331938 Get It

Purpose We hypothesized that surrogate markers of host immune response may predict survival in myeloid malignancies. Because of immediate practical applicability, we chose plasma immunoglobulin free light chain (FLC) concentration as the biomarker of interest. Patients and Methods Two independent cohorts of patients with primary myelofibrosis (PMF) or myelodysplastic syndromes (MDS) were studied. Kappa (κ) and lambda (λ) FLCs were measured by a quantitative nephelometric assay. Patients with monoclonal FLC were excluded. Results Values that were above the upper limit of normal for κ or λ FLC were documented in 33% of 240 patients with PMF and 46% of 74 patients with MDS. Increased FLC was significantly associated with increased creatinine, and advanced age in PMF (P < .001) and hemoglobin less than 10 g/dL in MDS (P = .005). In multivariable analysis, increased FLC predicted shortened survival in both PMF and MDS, independent of age, creatinine, and other conventional risk factors. Cutoff levels based on receiver operating characteristic analysis for κ plus λ total FLCs delineated risk groups with highly significant differences in overall survival; International Prognostic Scoring System–adjusted hazard ratio in PMF was 1.9 (95% CI, 1.3 to 2.7), and was 6.3 (95% CI, 2.7 to 16.6) in MDS. No correlations were seen with leukemia-free survival, karyotype, or JAK2, MPL, or IDH mutations. In patients with PMF who were studied by cytokine profiling, the prognostic value of an increased FLC level was independent of that from circulating interleukin-2 receptor (IL-2R) or IL-8 levels. Conclusion Increased plasma FLC concentration predicts inferior survival in both PMF and MDS. Its lack of correlation with leukemia-free survival and tumor-specific genetic markers suggests a primarily host-driven biologic phenomenon that might be more broadly applicable.
JAK inhibitors for myeloproliferative neoplasms: clarifying facts from myths
Tefferi, Ayalew

Mayo Clinic

Blood | January 27, 2012 | Volume: 119 | Issue: 12 | Pages: 2721-2730

10.1182/blood-2011-11-395228 | PMID 22279053 Get It

Abstract On November 16, 2011, the Food and Drug Administration approved ruxolitinib (a JAK1 and JAK2 inhibitor) for use in the treatment of high and intermediate risk myelofibrosis. This is welcome news for those patients in whom such therapy is indicated and treatment benefit outweighs attendant risk. The question is who are these patients, what should they expect in terms of both short-term effects and long-term impact, and why would they choose ruxolitinib over other JAK inhibitors that are freely available for use in a research setting. Ruxolitinib and most other JAK inhibitors exert a salutary effect on constitutional symptoms and splenomegaly but have yet to produce histopathologic or cytogenetic remissions, reverse bone marrow fibrosis, or improve survival over best supportive care. Furthermore, the palliative value of JAK inhibitors is diminished by notable side effects, including anemia, thrombocytopenia, gastrointestinal disturbances, metabolic abnormalities, peripheral neuropathy, and hyperacute relapse of symptoms during treatment discontinuation. Therefore, risk-benefit balance favors use of currently available JAK inhibitors in only a select group of patients with myelofibrosis, and their potential value in polycythemia vera, outside of special circumstances (eg, intractable pruritus), is undermined by the absence of evidence for a disease-modifying effect and presence of arguably superior alternatives.
Initial bone marrow reticulin fibrosis in polycythemia vera exerts an impact on clinical outcome
Barbui, Tiziano , Thiele, Jürgen, Passamonti, Francesco , Rumi, Elisa , Boveri, Emanuela , Randi, Maria Luigia , Bertozzi, Irene , Pieri, Lisa , Rotunno, Giada, Gisslinger, Heinz , Gisslinger, Bettina, Müllauer, Leonhard , Carobbio, Alessandra , Gianatti, Andrea , Ruggeri, Marco , Nichele, Ilaria , d'Amore, Emanuele S. G. , Rambaldi, Alessandro , Tefferi, Ayalew , Marino, Filippo , Vannucchi, Alessandro M. , Finazzi, Guido , dʼAmore, Emanuele S.G. , Rambaldi, Alessandro , Passamonti, Francesco

Mayo Clinic

Blood | January 14, 2012 | Volume: 119 | Issue: 10 | Pages: 2239-2241

10.1182/blood-2011-11-393819 | PMID 22246040 Get It

Abstract We examined the prevalence and prognostic relevance of bone marrow reticulin fibrosis in 526 patients with World Health Organization–defined polycythemia vera evaluated at the time of initial diagnosis. Seventy-four patients (14%) displayed mostly grade 1 reticulin fibrosis, with only 2 cases showing higher-grade fibrosis. Presenting clinical and laboratory characteristics, including JAK2V617F allele burden, between patients with and without fibrosis were similar for the most part, with the exception of a higher prevalence of palpable splenomegaly in patients with fibrosis (P < .01). Patients with fibrosis were less prone to experience thrombosis during their clinical course (1.1 vs 2.7 per 100 patient-years; P = .03) and more prone to develop post-polycythemia vera myelofibrosis (2.2 vs 0.8 per 100 patient-years; P = .01). There was no significant difference between the 2 groups in terms of overall or leukemia-free survival. The present study clarifies the incidence, degree, and prognostic relevance of bone marrow fibrosis obtained at time of initial diagnosis of polycythemia vera.
SF3B1 mutations are prevalent in myelodysplastic syndromes with ring sideroblasts but do not hold independent prognostic value
Patnaik, Mrinal M. , Hodnefield, Janice M., Knudson, Ryan A., Ketterling, Rhett P. , Garcia‐Manero, Guillermo , Steensma, David P. , Pardanani, Animesh , Hanson, Curtis A. , Tefferi, Ayalew , Lasho, Terra L. , Ketterling, Rhett P , Steensma, David P

Mayo Clinic

Blood | November 17, 2011 | Volume: 119 | Issue: 2 | Pages: 569-572

10.1182/blood-2011-09-377994 | PMID 22096241 Get It

SF3B1 mutations were recently reported in myelodysplastic syndromes (MDSs), especially in the presence of ring sideroblasts (RSs). We sought to define the interaction between SF3B1 mutations, morphology, karyotype, and prognosis in MDS with more than or equal to 15% RS (MDS-RS). We studied 107 patients with MDS-RS, including 48 with refractory anemia with RS (RARS), 43 with refractory cytopenia with multilineage dysplasia (RCMD)-RS, 11 with refractory anemia with excess blasts-1 (RAEB1)–RS, and 5 with RAEB2-RS. SF3B1 mutations were detected in 53 (∼ 50%) patients: 35 RARS (73%), 16 RCMD-RS (37%), and 2 RAEB1-RS (18%). In univariate analysis, the presence of SF3B1 mutations was associated with better overall (P < .01) and leukemia-free (P < .01) survival; however, in both instances, significance was completely accounted for by World Health Organization morphologic risk categorization. In other words, when RARS and RCMD-RS were analyzed separately, there was no additional prognostic value from the presence or absence of SF3B1 mutations.
Predictors of greater than 80% 2-year mortality in primary myelofibrosis: a Mayo Clinic study of 884 karyotypically annotated patients
Tefferi, Ayalew , Jimma, Thitina, Gangat, Naseema , Vaidya, Rakhee , Begna, Kebede H. , Hanson, Curtis A. , Dyke, Daniel L. Van , Caramazza, Domenica , Pardanani, Animesh

Mayo Clinic

Blood | September 1, 2011 | Volume: 118 | Issue: 17 | Pages: 4595-4598

10.1182/blood-2011-08-371096 | PMID 21881047 Get It

Abstract DIPSS-plus (the Dynamic International Prognostic Scoring System-plus) includes 8 risk factors for survival in primary myelofibrosis. In the present study of 884 karyotypically annotated patients with primary myelofibrosis, we sought to identify 1 or 2 parameters that can reliably predict death in the first 2 years of disease. After a median of 8.2 years from time of referral to the Mayo Clinic, 564 deaths (64% of patients in the study) had been recorded. Risk factors associated with > 80% 2-year mortality included monosomal karyotype, inv(3)/i(17q) abnormalities, or any 2 of the following: circulating blasts > 9%, leukocytes ≥ 40 × 109/L, or other unfavorable karyotype. Patients with any 1 of these risk profiles (n = 52) displayed significantly shorter overall survival than those otherwise belonging to a high-risk category per DIPSS-plus (n = 298); respective median survivals were 9 and 23 months (hazard ratio 2.2, 95% confidence interval 1.6-3.1; P < .01). The present information complements DIPSS-plus in the selection of primary myelofibrosis patients for high-risk treatment approaches.
Survival and Disease Progression in Essential Thrombocythemia Are Significantly Influenced by Accurate Morphologic Diagnosis: An International Study
Barbui, Tiziano , Thiele, Jüergen, Passamonti, Francesco , Rumi, Elisa , Boveri, Emanuela , Ruggeri, Marco , Rodeghiero, Francesco, dʼAmore, Emanuele S.G. , Randi, Maria Luigia , Bertozzi, Irene , Antonioli, Elisabetta , Carrai, Valentina , Gisslinger, Heinz , Buxhofer‐Ausch, Veronika , Müllauer, Leonhard , Carobbio, Alessandra , Gianatti, Andrea , Gangat, Naseema , Hanson, Curtis A. , Tefferi, Ayalew , Marino, Filippo , Vannucchi, Alessandro M. , Passamonti, Francesco

Mayo Clinic

Journal of Clinical Oncology | July 12, 2011 | Volume: 29 | Issue: 23 | Pages: 3179-3184

10.1200/jco.2010.34.5298 | PMID 21747083 Get It

Purpose The WHO diagnostic criteria underscore the role of bone marrow (BM) morphology in distinguishing essential thrombocythemia (ET) from early/prefibrotic primary myelofibrosis (PMF). This study examined the clinical relevance of such a distinction. Methods Representatives from seven international centers of excellence for myeloproliferative neoplasms convened to create a clinicopathologic database of patients previously diagnosed as having ET (N = 1,104). Study eligibility criteria included availability of treatment-naive BM specimens obtained within 1 year of diagnosis. All bone marrows subsequently underwent a central re-review. Results Diagnosis was confirmed as ET in 891 patients (81%) and was revised to early/prefibrotic PMF in 180 (16%); 33 patients were not evaluable. In early/prefibrotic PMF compared with ET, the 10-year survival rates (76% and 89%, respectively) and 15-year survival rates (59% and 80%, respectively), leukemic transformation rates at 10 years (5.8% and 0.7%, respectively) and 15 years (11.7% and 2.1%, respectively), and rates of progression to overt myelofibrosis at 10 years (12.3% and 0.8%, respectively) and 15 years (16.9% and 9.3%) were significantly worse. The respective death, leukemia, and overt myelofibrosis incidence rates per 100 patient-years for early/prefibrotic PMF compared with ET were 2.7% and 1.3% (relative risk [RR], 2.1; P < .001), 0.6% and 0.1% (RR, 5.2; P = .001), and 1% and 0.5% (RR, 2.0; P = .04). Multivariable analysis confirmed these findings and also identified age older than 60 years (hazard ratio [HR], 6.7), leukocyte count greater than 11 × 10 9 /L (HR, 2.01), anemia (HR, 2.95), and thrombosis history (HR, 2.81) as additional risk factors for survival. Thrombosis and JAK2V617F incidence rates were similar between the two groups. Survival in ET was similar to the sex- and age-standardized European population. Conclusion This study validates the clinical relevance of strict adherence to WHO criteria in the diagnosis of ET and provides important information on survival, disease complication rates, and prognostic factors in strictly WHO-defined ET and early/prefibrotic PMF.
The Myeloproliferative Neoplasm Symptom Assessment Form (MPN-SAF): International Prospective Validation and Reliability Trial in 402 patients
Scherber, Robyn M. , Dueck, Amylou C. , Johansson, Peter , Barbui, Tiziano , Passamonti, Francesco , Andréasson, Björn , Ferarri, Maria L, Rambaldi, Alessandro , Samuelsson, Jan , Birgegård, Gunnar , Tefferi, Ayalew , Harrison, Claire , Radia, Deepti , Barosi, Giovanni , Vannucchi, Alessandro M. , Mesa, Ruben A. , Dueck, A. C. , Rambaldi, Alessandro , Passamonti, Francesco

Mayo Clinic

Blood | May 2, 2011 | Volume: 118 | Issue: 2 | Pages: 401-408

10.1182/blood-2011-01-328955 | PMID 21536863 Get It

Abstract Symptomatic burden in myeloproliferative neoplasms is present in most patients and compromises quality of life. We sought to validate a broadly applicable 18-item instrument (Myeloproliferative Neoplasm Symptom Assessment Form [MPN-SAF], coadministered with the Brief Fatigue Inventory) to assess symptoms of myelofibrosis, essential thrombocythemia, and polycythemia vera among prospective cohorts in the United States, Sweden, and Italy. A total of 402 MPN-SAF surveys were administered (English [25%], Italian [46%], and Swedish [28%]) in 161 patients with essential thrombocythemia, 145 patients with polycythemia vera, and 96 patients with myelofibrosis. Responses among the 3 administered languages showed great consistency after controlling for MPN subtype. Strong correlations existed between individual items and key symptomatic elements represented on both the MPN-SAF and the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire-C30. Enrolling physicians' blinded opinion of patient symptoms (6 symptoms assessed) were highly correlated with corresponding patients' responses. Serial administration of the English MPN-SAF among 53 patients showed that most MPN-SAF items are well correlated (r > 0.5, P < .001) and highly reproducible (intraclass correlation coefficient > 0.7). The MPN-SAF is a comprehensive and reliable instrument that is available in multiple languages to evaluate symptoms associated with all types of MPNs in clinical trials globally.
A CK2-dependent mechanism for activation of the JAK-STAT signaling pathway
Zheng, Ying , Qin, Hongwei , Frank, Stuart J. , Deng, Luqin, Litchfield, David W. , Tefferi, Ayalew , Pardanani, Animesh , Lin, Fang‐Tsyr , Li, Jingzhi , Sha, Bingdong , Benveniste, Etty

Mayo Clinic

Blood | April 29, 2011 | Volume: 118 | Issue: 1 | Pages: 156-166

10.1182/blood-2010-01-266320 | PMID 21527517 Get It

AbstractJAK-STAT signaling is involved in the regulation of cell survival, proliferation, and differentiation. JAK tyrosine kinases can be transiently activated by cytokines or growth factors in normal cells, whereas they become constitutively activated as a result of mutations that affect their function in tumors. Specifically, the JAK2V617F mutation is present in the majority of patients with myeloproliferative disorders (MPDs) and is implicated in the pathogenesis of these diseases. In the present study, we report that the kinase CK2 is a novel interaction partner of JAKs and is essential for JAK-STAT activation. We demonstrate that cytokine-induced activation of JAKs and STATs and the expression of suppressor of cytokine signaling 3 (SOCS-3), a downstream target, are inhibited by CK2 small interfering RNAs or pharmacologic inhibitors. Endogenous CK2 is associated with JAK2 and JAK1 and phosphorylates JAK2 in vitro. To extend these findings, we demonstrate that CK2 interacts with JAK2V617F and that CK2 inhibitors suppress JAK2V617F autophosphorylation and downstream signaling in HEL92.1.7 cells (HEL) and primary cells from polycythemia vera (PV) patients. Furthermore, CK2 inhibitors potently induce apoptosis of HEL cells and PV cells. Our data provide evidence for novel cross-talk between CK2 and JAK-STAT signaling, with implications for therapeutic intervention in JAK2V617F-positive MPDs.